Incidence and Demographic and Tumor Characteristics of HER2-Positive Invasive Breast Cancer in a Large, Unselected Population, 2000-2006

被引：0
|
作者：
Fehrenbacher, L. [1 ]
Habel, L. A. [1 ]
Capra, A. M. [1 ]
Anthony, A. T. [1 ]
Li, X. [1 ]
Quesenberry, C. P. [1 ]
Fulton, R. [1 ]
机构：
[1] Kaiser Permanente, NCal, Oakland, CA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：665S / 665S
页数：1
相关论文
共 50 条
  • [1] Is tumor size important in HER2-positive breast cancer?
    Parise, C.
    Bauer, K.
    Caggiano, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] HER2-Positive Circulating Tumor Cells in Breast Cancer
    Ignatiadis, Michail
    Rothe, Francoise
    Chaboteaux, Carole
    Durbecq, Virginie
    Rouas, Ghizlane
    Criscitiello, Carmen
    Metallo, Jessica
    Kheddoumi, Naima
    Singhal, Sandeep K.
    Michiels, Stefan
    Veys, Isabelle
    Rossari, Jose
    Larsimont, Denis
    Carly, Birgit
    Pestrin, Marta
    Bessi, Silvia
    Buxant, Frederic
    Liebens, Fabienne
    Piccart, Martine
    Sotiriou, Christos
    [J]. PLOS ONE, 2011, 6 (01):
  • [3] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    [J]. LANCET, 2017, 389 (10087): : 2415 - 2429
  • [4] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [5] Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer
    Kotoula, V.
    Giannoulatou, E.
    Kouvatseas, G.
    Tikas, I.
    Lazaridis, G.
    Charalambous, E.
    Efstratiou, I.
    Bobos, M.
    Tsolaki, E.
    Zagouri, F.
    Christodoulou, C.
    Pentheroudakis, G.
    Koutras, A.
    Papakostas, P.
    Kosmidis, P. A.
    Pectasides, D.
    Fountzilas, G.
    [J]. CANCER RESEARCH, 2017, 77
  • [6] Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis
    Collova, Elena
    Ferzi, Antonella
    Scandurra, Giuseppa
    Aurilio, Gaetano
    Torri, Valter
    Porcu, Luca
    Sano, Maria Vita
    Taibi, Eleonora
    Foglietta, Jennifer
    Generali, Daniele
    Andreis, Daniele
    Dazzani, Maria Chiara
    Bramati, Annalisa
    Marcon, Ilaria
    Atzori, Francesco
    Cinieri, Saverio
    Tondulli, Luca
    Grasso, Donatalla
    Nole, Franco
    Petrella, Maria Cristina
    Gori, Stefania
    La Verde, Nicla
    [J]. TUMORI, 2014, 100 (04) : 426 - 431
  • [7] Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer
    Mustafa, Rose E.
    DeStefano, Lauren M.
    Bahng, Joey
    Yoon-Flannery, Kahyun
    Fisher, Carla S.
    Zhang, Paul J.
    Tchou, Julia
    Czerniecki, Brian J.
    De la Cruz, Lucy M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (10) : 2999 - 3003
  • [8] Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer
    Rose E. Mustafa
    Lauren M. DeStefano
    Joey Bahng
    Kahyun Yoon-Flannery
    Carla S. Fisher
    Paul J. Zhang
    Julia Tchou
    Brian J. Czerniecki
    Lucy M. De La Cruz
    [J]. Annals of Surgical Oncology, 2017, 24 : 2999 - 3003
  • [9] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    [J]. BREAST, 2014, 23 (02): : 128 - 136
  • [10] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
12345